This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Harold Wilkinson, MD, PhD
Division of Neurosurgery Department of Surgery University of Massachusetts Medical Center 55 Lake Ave N Worcester, MA 06155

Arch Neurol. 1989;46(7):721.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—I was disappointed to read Dr Dewey Nelson's latest contribution, "Dangers From Methylprednisolone Acetate Therapy by Intraspinal Injection," in the July 1988 issue of the ARCHIVES,¹ to his long-standing crusade against intrathecal use of depository methylprednisolone acetate, not because he has correctly drawn attention to the potential risk of this therapy, but because his strong feelings on the subject have added immeasurably to the misery of those patients in whom the risk-benefit ratio of this therapy clearly justifies its use. In his zeal, Dr Nelson has ignored the considerable body of published literature and experience that attests to the benefit of intrathecal and epidural methylprednisolone acetate injections in patients whose lives have been made miserable from adhesive arachnoiditis, or other painful spinal conditions. My own experience with intrathecally administered methylprednisolone acetate therapy, which has been presented at several meetings and is being prepared for publication, has . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?